


PCT/US03/11008
19EA/US 19 July 2001

CLAIMS

What is claimed is:


1. A resveratrol derivative having the formula;



wherein:


$$R_1 = OH \text{ and } R_2 = R_3 = -OCH_3.$$

2. A resveratrol derivative having the formula;



wherein $R_4 = R_5 = -OCH_3$ and $R_6 = -OH$.


3. A resveratrol derivative having the formula;



wherein $R_7 = R_8 = -OH$ and $R_9 = -OCH_3$.

PCT/US03/11008
19CA/US 19 July 2

4. A resveratrol derivative having the formula:




selected from the group consisting of compounds wherein:


- a) $R_{10} = R_{11} = -OCH_3$ and $R_{12} = -O(PO)(OBn)_2$; and
- b) $R_{10} = R_{11} = -OCH_3$ and $R_{12} = -O(PO)(ONa)_2$.

5. [Deleted]


6. A method for synthesizing the resveratrol derivative of claim 1 wherein $R_1 = -OH$ and $R_2 = R_3 = -OCH_3$, comprising the following steps:




PC7/MS03/11008
1P8A/US 19 JULY 2008




7. A method for synthesizing the resveratrol derivative of claim 2 comprising the following steps:




8. A method for synthesizing the resveratrol derivative of claim 3 comprising the following steps:




POT/US03/11008
19A/MS 19 JULY 200





9. A method for synthesizing the resveratrol derivative of claim 4 wherein R₁₀ = R₁₁ = -OCH₃ and R₁₂ = -O(PO)(OBn)₂, comprising the following steps:







PG1/us03/11008
19SA/us 19 JULY 200




10. A method for synthesizing the resveratrol derivative of claim 4 wherein R₁₀=R₁₁=-OCH₃ and R₁₂=-O(PO)(ONa)₂, comprising the following steps:





PCT/US03/11008
PCT/US 19 July 200



11. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising the compound of claim 2, or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising the compound of claim 3, or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising the compound of claim 4, or a pharmaceutically acceptable salt thereof.
15. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 1 or its trans isomer, or a pharmaceutically acceptable salt thereof.

16. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 2, or a pharmaceutically acceptable salt thereof.
17. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 3 or its trans isomer, or a pharmaceutically acceptable salt thereof.
18. A method for treating humans and mammals afflicted with cancer, comprising administering a physiologically effective amount of the compound of claim 4, or a pharmaceutically acceptable salt thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.